Abstract
Complex traits, including migraine, often aggregate in families, but the underlying genetic architecture behind this is not well understood. The aggregation could be explained by rare, penetrant variants that segregate according to Mendelian inheritance or by the sufficient polygenic accumulation of common variants, each with an individually small effect, or a combination of the two hypotheses. In 8,319 individuals across 1,589 migraine families, we calculated migraine polygenic risk scores (PRS) and found a significantly higher common variant burden in familial cases (n = 5,317, OR = 1.76, 95% CI = 1.71–1.81, p = 1.7 × 10 −109 ) compared to population cases from the FINRISK cohort (n = 1,101, OR = 1.32, 95% CI = 1.25–1.38, p = 7.2 × 10 −17 ). The PRS explained 1.6% of the phenotypic variance in the population cases and 3.5% in the familial cases (including 2.9% for migraine without aura, 5.5% for migraine with typical aura, and 8.2% for hemiplegic migraine). The results demonstrate a significant contribution of common polygenic variation to the familial aggregation of migraine. Gormley et al. use polygenic risk scores to show that common variation, captured by genome-wide association studies, in combination contributes to the aggregation of migraine in families. The results may have similar implications for other complex traits in general.
| Original language | English |
|---|---|
| Pages (from-to) | 743-753.e4 |
| Journal | Neuron |
| Volume | 98 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 16 May 2018 |
Funding
This work was supported by the Wellcome Trust (grant numbers WT089062 , 098051 to A.P.); the Academy of Finland (grant numbers 286500 , 293404 to A.P., and 139795 to M.W.); the Academy of Finland Center of Excellence for Complex Disease Genetics (grant number 312074 ); the EuroHead project ( LSM-CT-2004-504837 to A.P.); FP7-EUROHEADPAIN (grant number 602633 to A.P.); ENGAGE Consortium (grant agreement HEALTH-F4-2007-201413 to A.P.); EU/SYNSYS-Synaptic Systems (grant number 242167 to A.P.); the Sigrid Juselius Foundation, Finland (to A.P.); the Nordic Information for Action eScience Center, NIASC (Grant No 62721 to A.P.); NIH /Genomic strategies to identify high-impact psychiatric risk variants (Grant No 1U01MH105666-01 to A.P.); the Folkh\u00E4lsan Research Foundation, Finland (to M.W.); Medicinska Underst\u00F6dsf\u00F6reningen Liv & H\u00E4lsa, Finland (to M.W.); the Helsinki University Central Hospital (to M.K., M.F., V.A.); the Swedish Research Foundation (grant number 2017-01096 to A.C.B.); the Swedish Brain Foundation (to A.C.B. and C.R.); and Karolinska Institutet Research Funds (to A.C.B.). T.L. was supported by the Academy of Finland : grants 286284 , 134309 (Eye), 126925 , 121584 , 124282 , 129378 (Salve), 117787 (Gendi), and 41071 (Skidi); the Social Insurance Institution of Finland ; Competitive State Research Financing of the Expert Responsibility area of Kuopio, Tampere and Turku University Hospitals (grant X51001 ); Juho Vainio Foundation ; Paavo Nurmi Foundation; Finnish Foundation for Cardiovascular Research ; Finnish Cultural Foundation ; Tampere Tuberculosis Foundation ; Emil Aaltonen Foundation ; Yrj\u00F6 Jahnsson Foundation ; Signe and Ane Gyllenberg Foundation ; Diabetes Research Foundation of Finnish Diabetes Association ; and EU Horizon 2020 (grant 755320 for TAXINOMISIS). The work was further supported by funding from Merck and Co. , Kenilworth, NJ, USA. We would like to thank the participants of the NFBC1966 study and the NFBC project center. We are sincerely grateful to all members of the Finnish migraine families for participating in this research. We would also like to thank the research participants and employees of 23andMe, Inc., a personal genetics company, for making this work possible. The study was partially funded by Merck and Co., Kenilworth, NJ, USA. Members of the 23andMe Research Team are current or former employees of 23andMe, Inc. and hold stock or stock options in 23andMe.
| Funders | Funder number |
|---|---|
| Academy of Finland Center of Excellence for Complex Disease Genetics | LSM-CT-2004-504837, 312074, FP7-EUROHEADPAIN, 602633 |
| ENGAGE Consortium | HEALTH-F4-2007-201413 |
| EU/SYNSYS-Synaptic Systems | 242167 |
| Medicinska Understödsföreningen Liv & Hälsa, Finland | |
| Merck and Co. | |
| NIASC | 62721 |
| Nordic Information for Action eScience Center | |
| National Institutes of Health | |
| National Institute of Mental Health | U01MH105666 |
| Merck | |
| Helsingin ja Uudenmaan Sairaanhoitopiiri | |
| Yrjö Jahnssonin Säätiö | |
| Wellcome Trust | WT089062, 098051 |
| Folkhälsanin Tutkimussäätiö | |
| Swedish Foundation for MS Research | 2017-01096 |
| Academy of Finland | 293404, 286500, 139795 |
| Suomen Kulttuurirahasto | |
| Hjärnfonden | |
| Juho Vainion Säätiö | |
| Karolinska Institutet | 126925, 121584, 129378, 117787, 134309, 286284, 41071, 124282 |
| Signe ja Ane Gyllenbergin Säätiö | |
| Emil Aaltosen Säätiö | |
| Sydäntutkimussäätiö | |
| Sigrid Juséliuksen Säätiö | |
| Tampereen Tuberkuloosisäätiö | |
| Horizon 2020 | 755320 |
| Diabetesliitto | |
| Paavo Nurmen Säätiö | |
| Turun Yliopistollinen Keskussairaala | X51001 |
Keywords
- disease aggregation
- familial aggregation
- families
- genome-wide association study
- GWAS
- hemiplegic migraine
- migraine
- migraine with aura
- polygenic risk score
- PRS
Cohort Studies
- Netherlands Twin Register (NTR)